BD Completes Clinical Trial for Wearable Injector
BD (Becton, Dickinson and Company), a leading global medical technology company, recently announced the completion of a 50-subject human clinical trial with the BD Libertas Wearable Injector.
The award-winning injector is a subcutaneous drug delivery system, currently in development, that is designed to require no patient assembly and deliver biologics with viscosities up to 50 cP in 2-mL to 5-mL and 5-mL to 10-mL configurations.
The BD independently sponsored and conducted study was designed to evaluate the performance of the 5-mL BD Libertas device in human subjects, including tissue effects, skin reactivity and patient acceptance. The results are expected to be announced early 2020.
The study represents the most recent in a series of over 50 BD-conducted preclinical and clinical studies intended to measure the performance of the BD Libertas Wearable Injector, demonstrate feasibility of 2-mL to 10-mL biologic injections into subcutaneous tissue and characterize tissue response to large volume injections in human and animal subjects.
Peter Nolan, Worldwide President, BD Pharmaceutical Systems, said “BD is committed to bringing value to our pharma partnerships, including providing them with independent BD-sponsored and generated study data to accelerate combination product development. The recent study reflects BD’s continued investment in solutions to meet pharma’s needs by expanding the design space for biologics delivery.”
BD is one of the largest global medical technology companies and is advancing healthcare by improving medical discovery, diagnostics and care delivery. The company supports the heroes that work on the frontline by developing innovative technology, services and solutions, to advance clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.
Total Page Views: 285